{
    "nct_id": "NCT06216249",
    "official_title": "A Phase 2 Randomized Trial in Patients With Metastatic Castration Resistant Prostate Cancer to Determine the Efficacy of a Flexible Dosing Schedule of Lu-PSMA Treatment up to 12 Cycles Including Potential Treatment Holiday Periods in Comparison to the Standard Fixed Dosing Schedule of Six Cycles Every Six Weeks (FLEX-MRT)",
    "inclusion_criteria": "* Patients must have prostate cancer proven by histopathology\n* Patients must have ≥ 1 metastatic lesion by any imaging (CT, magnetic resonance imaging [MRI], bone scan, PET)\n* Patients must have received at least one regimen of chemotherapy for mCRPC\n* Patients must have received at least one androgen-receptor signaling inhibitors (ARSI)\n* Patients must be eligible by PSMA PET VISION criteria. PSMA PET/CT must be performed within 8 weeks of planned first cycle of 177Lu-PSMA-617\n* White blood cell (WBC) ≥ 2,500/ul\n* Platelets (PLT) ≥ 100,000/ul\n* Hemoglobin (Hb) ≥ 9.0 g/dl\n* Absolute neutrophil count (ANC) ≥ 1,500 ul\n* Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n* Patients must be adults ≥ 18 years of age\n* Patients must have the ability to understand and sign an approved informed consent form (ICF)\n* Patients must have the ability to understand and comply with all protocol requirements\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior cycle of 177Lu-PSMA-617 therapy\n* Less than 6 weeks between last myelosuppressive therapy (including docetaxel, cabazitaxel, strontium-89, samarium-153, rhenium-186, rhenium-188, radium-223, hemi-body irradiation) and first cycle of 177Lu-PSMA-617 therapy\n* Glomerular filtration rate (GFR) < 50 ml/min\n* Urinary tract obstruction or marked hydronephrosis",
    "miscellaneous_criteria": ""
}